Literature DB >> 16455920

Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.

Francisco M Marty1, Wendy W Yeh, Christine B Wennersten, Lata Venkataraman, Esperanza Albano, Edwin P Alyea, Howard S Gold, Lindsey R Baden, Satish K Pillai.   

Abstract

The emergence of a clinically daptomycin-resistant Staphylococcus aureus isolate occurred during treatment of methicillin-resistant S. aureus bacteremia and probable vertebral osteomyelitis. The breakthrough isolate was indistinguishable from pretreatment daptomycin-susceptible isolates by pulsed-field gel electrophoresis. Daptomycin nonsusceptibility was confirmed by MIC and time-kill curve analyses.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16455920      PMCID： PMC1392688          DOI： 10.1128/JCM.44.2.595-597.2006

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  13 in total

1.  Resistance studies with daptomycin.

Authors:  J A Silverman; N Oliver; T Andrew; T Li
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Principles of antimicrobial therapy in the transplant patient.

Authors:  R H Rubin; F M Marty
Journal:  Transpl Infect Dis       Date:  2004-09       Impact factor: 2.228

Review 3.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

4.  Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.

Authors:  Kerry L LaPlante; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

5.  Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact.

Authors:  Jared A Silverman; Lawrence I Mortin; Andrew D G Vanpraagh; Tongchuan Li; Jeff Alder
Journal:  J Infect Dis       Date:  2005-05-05       Impact factor: 5.226

6.  Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits.

Authors:  J T Mader; K Adams
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

7.  In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.

Authors:  Laura A Jevitt; Amanda J Smith; Portia P Williams; Patti M Raney; John E McGowan; Fred C Tenover
Journal:  Microb Drug Resist       Date:  2003       Impact factor: 3.431

8.  The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.

Authors:  Robert D Arbeit; Dennis Maki; Francis P Tally; Edward Campanaro; Barry I Eisenstein
Journal:  Clin Infect Dis       Date:  2004-05-20       Impact factor: 9.079

Review 9.  Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.

Authors:  Christopher F Carpenter; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2004-03-11       Impact factor: 9.079

10.  Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms.

Authors:  Jennifer M Streit; Ronald N Jones; Helio S Sader
Journal:  J Antimicrob Chemother       Date:  2004-02-25       Impact factor: 5.790
View more
  65 in total

1.  Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycin-resistant isolates of Staphylococcus aureus.

Authors:  Aileen Rubio; Mary Conrad; Robert J Haselbeck; Kedar G C; Vickie Brown-Driver; John Finn; Jared A Silverman
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

2.  Impact of daptomycin resistance on Staphylococcus aureus virulence.

Authors:  David R Cameron; Lawrence I Mortin; Aileen Rubio; Eleftherios Mylonakis; Robert C Moellering; George M Eliopoulos; Anton Y Peleg
Journal:  Virulence       Date:  2015       Impact factor: 5.882

3.  Exposure of Staphylococcus aureus to Targocil Blocks Translocation of the Major Autolysin Atl across the Membrane, Resulting in a Significant Decrease in Autolysis.

Authors:  Kiran B Tiwari; Craig Gatto; Suzanne Walker; Brian J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

4.  In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes.

Authors:  Kerin L Tyrrell; Diane M Citron; Yumi A Warren; Helen T Fernandez; C Vreni Merriam; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

5.  Electrostatic-Mediated Affinity Tuning of Lysostaphin Accelerates Bacterial Lysis Kinetics and Enhances In Vivo Efficacy.

Authors:  Hongliang Zhao; Susan Eszterhas; Jacob Furlon; Hao Cheng; Karl E Griswold
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

6.  daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  Warren E Rose; Steven N Leonard; George Sakoulas; Glenn W Kaatz; Marcus J Zervos; Anjly Sheth; Christopher F Carpenter; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2007-11-12       Impact factor: 5.191

7.  Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.

Authors:  Ilana Lopes Baratella da Cunha Camargo; Hui-Min Neoh; Longzhu Cui; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

8.  Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.

Authors:  Tiffanny Jones; Michael R Yeaman; George Sakoulas; Soo-Jin Yang; Richard A Proctor; Hans-Georg Sahl; Jacques Schrenzel; Yan Q Xiong; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

9.  Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  J M Miró; C García-de-la-Mària; Y Armero; D Soy; A Moreno; A del Río; M Almela; M Sarasa; C A Mestres; J M Gatell; M T Jiménez de Anta; F Marco
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

Review 10.  Daptomycin in bone and joint infections: a review of the literature.

Authors:  Dennis A K Rice; Luke Mendez-Vigo
Journal:  Arch Orthop Trauma Surg       Date:  2008-11-07       Impact factor: 3.067
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.